Variables | All patients (n = 34) | SV responders (n = 19) | SV non-responders (n = 15) | P value a |
---|---|---|---|---|
Age (years, mean ± SD) | 70 ± 12 | 69 ± 13 | 73 ± 11 | 0.368 |
Gender [Male, n (%)] | 24 (71%) | 14 (74%) | 10 (67%) | 0.718 |
Body mass index (kg/m2, mean ± SD) | 22.5 ± 3.1 | 22.6 ± 3.1 | 22.5 ± 3.3 | 0.932 |
Body surface area (m2, mean ± SD) | 1.65 ± 0.16 | 1.68 ± 0.17 | 1.62 ± 0.16 | 0.300 |
APACHE II score (mean ± SD) | 20 ± 6 | 21 ± 5 | 20 ± 6 | 0.644 |
SOFA score (mean ± SD) | 9 ± 3 | 9 ± 3 | 8 ± 2 | 0.554 |
Source of infection, n (%) | ||||
Lung | 18 (53%) | 11 (58%) | 7 (47%) | 0.730 |
Urinary tract | 7 (21%) | 3 (16%) | 4 (27%) | 0.672 |
Abdomen | 7 (21%) | 5 (26%) | 2 (13%) | 0.426 |
Bloodstream | 7 (21%) | 3 (16%) | 4 (27%) | 0.672 |
Others | 4 (12%) | 2 (11%) | 2 (13%) | 1.000 |
Co-morbidities, n (%) | ||||
Hypertension | 16 (47%) | 9 (47%) | 7 (47%) | 1.000 |
Diabetes | 10 (29%) | 7 (37%) | 3 (20%) | 0.451 |
Chronic obstructive pulmonary disease | 3 (9%) | 2 (11%) | 1 (7%) | 1.000 |
Coronary heart disease | 2 (6%) | 2 (11%) | 0 (0%) | 0.492 |
Chronic kidney disease | 2 (6%) | 1 (5%) | 1 (7%) | 1.000 |
Pathogen type in culture, n (%) | ||||
Gram-negative | 15 (44%) | 9 (47%) | 6 (40%) | 0.624 |
Gram-positive | 1 (3%) | 1 (5%) | 0 (0%) | |
Mixed | 2 (6%) | 1 (5%) | 1 (7%) | |
Fungus | 2 (6%) | 0 (0%) | 2 (13%) | |
No pathogen | 14 (41%) | 8 (42%) | 6 (40%) | |
Patients receiving IMV, n (%) | 24 (71%) | 15 (79%) | 9 (60%) | 0.276 |
PaO2/FiO2 (mean ± SD) | 262 ± 135 | 248 ± 134 | 285 ± 142 | 0.518 |
PEEP (cm H2O, mean ± SD) | 6 ± 1 | 5 ± 1 | 6 ± 2 | 0.479 |
Tidal volume (mL/kg of predicted body weight, mean ± SD) | 7.1 ± 1.3 | 6.8 ± 1.2 | 7.6 ± 1.3 | 0.129 |
Fentanyl, n (%) | 15 (44%) | 10 (53%) | 5 (33%) | 0.314 |
Midazolam, n (%) | 15 (44%) | 10 (53%) | 5 (33%) | 0.314 |
Propofol, n (%) | 18 (53%) | 11 (58%) | 7 (47%) | 0.730 |
Duration of IMV [days, median (IQR)] | 6 (3–12) | 6 (3–13) | 5 (3–16) | 0.719 |
Serum lactate level (mmol/L, mean ± SD) | 3.5 ± 2.7 | 2.9 ± 1.4 | 4.2 ± 3.7 | 0.194 |
Patients with left ventricular-arterial uncoupling before NE infusion, n (%) | 10 (29%) | 8 (42%) | 2 (13%) | 0.128 |
Time from NE infusion start to MAP stabilization [min, median (IQR)] | 95 (39–158) | 86 (37–180) | 100 (55–135) | 0.862 |
Cumulative fluid volume before NE infusion (mL, mean ± SD) | 1638 ± 569 | 1542 ± 523 | 1758 ± 620 | 0.278 |
Cumulative fluid volume during the study period [mL, median (IQR)] | 193 (90–309) | 180 (60–350) | 210 (120–305) | 0.490 |
Cumulative fluid volume within the first 24 h (mL, mean ± SD) | 3744 ± 1251 | 3389 ± 1181 | 4194 ± 1228 | 0.061 |
NE dose (μg/kg/min, median (IQR)) | 0.254 (0.131–0.556) | 0.22 (0.09–0.556) | 0.44 (0.182–0.556) | 0.167 |
Urine output (mL/kg/h, mean ± SD) | 1.32 ± 0.73 | 1.13 ± 0.41 | 1.55 ± 0.97 | 0.133 |
Duration of ICU stay [days, median (IQR)] | 7 (5–16) | 7 (6–16) | 12 (4–17) | 0.958 |
In-hospital mortality, n (%) | 9 (26%) | 6 (32%) | 3 (20%) | 0.485 |